EFFECTS OF DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE (C), THALIDOMIDE (T) AND DEXAMETHASONE (D) COMBINATION ON LYMPHOCYTE POPULATIONS OF TRANSPLANT ELIGIBLE NEWLY DIAGNOSE MULTIPLE MYELOMA PATIENTS

Background: The CTD combination have both an immunomodulatory and immunosuppressive activity on multiplemyeloma (MM) patients (pts) treatment. The advance of immunotherapy has been demonstrated by the development ofnew agents like anti CD38-antibody Dara, that are increasing the overall and progress...

Full description

Bibliographic Details
Main Authors: A Santos, H Santos, J Santos, L Lucas, M Salvino, A Almeida, M Santos, A Torres, MG Arruda, EQ Crusoe
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137921009032
_version_ 1818585183706677248
author A Santos
H Santos
J Santos
L Lucas
M Salvino
A Almeida
M Santos
A Torres
MG Arruda
EQ Crusoe
author_facet A Santos
H Santos
J Santos
L Lucas
M Salvino
A Almeida
M Santos
A Torres
MG Arruda
EQ Crusoe
author_sort A Santos
collection DOAJ
description Background: The CTD combination have both an immunomodulatory and immunosuppressive activity on multiplemyeloma (MM) patients (pts) treatment. The advance of immunotherapy has been demonstrated by the development ofnew agents like anti CD38-antibody Dara, that are increasing the overall and progression-free survival of MM pts. Daraeffect on the immune system was already described, but few studies analyzed specifically lymphocytes population. Wehypothesized that Dara-CTD combination could impact on lymphocytes subsets during treatment.Aims: The primary endpoint was to quantify subpopulations of lymphocytes in pts with newly diagnosed multiplemyeloma (NDMM) transplant eligible (TE) pts, during Dara-CTD treatment phases (induction, consolidation andmaintenance). Secondary endpoint was to describe B cells subsets during the same phases Methods: Peripheral blood of 14 pts at four different time points was collected: at diagnose, after four cycles of Dara-CTD, after two consolidation cycles post-autologous stem cell transplantation (ASCT) and before maintenance therapy.Flow cytometry was used to detect lymphocyte surface molecules including CD3, CD4, CD5, CD8, CD16, CD19, CD20,CD38, CD45 and CD56 in the scatter plot. B cells were isolated and subpopulations (naïve B cells, non-class switchedmemory B cells, class switched memory B cells, IgD-CD27- memory B cells and plasmablasts) were detected by CD20,CD24, CD27, CD38, CD45 and IgD. Statistics was performed using the SPSS®v25.0 Results: The pts median age was 55 range (41-65) years old, and 57% were female. The median of T, B and NKlymphocytes subsets at diagnosis were 1153 x 10³/μL, 205x 10³/μL and 284 x 10³/μL cells, respectively. After four cyclesof Dara-CTD the median of T, B and NK cells dropped significantly to 889 x 10³/μL, 12 x 10³/μL and 11 x 10³/μL,respectively (p<0.05). The number of the cells after two consolidation cycles post-ASCT, showed T cells full recovery(1087 x 10³/μL) while B and NK cells had weakly reconstitution (15 x 10³/μL and 34 x 10³/μL, respectively). Beforemaintenance therapy, the median of T, B and NK cells were 1456 x 10³/μL, 24 x 10³/μL and 33 x 10³/μL, respectively.Regarding B cell population, the median of naïve B cell decreased after 4 induction cycles from 32 x 10³/μL to 1 x 10³/μL.Then, after two consolidation cycles post-ASCT the number of B cell increased to 14 x 10³/μL and to 18 x 10³/μL beforemaintenance Summary/Conclusion: Lymphopenia have been shown with different protocols using Dara as single agent or incombination. The present study confirmed that there is a decrease in the number of different lymphocytes populations (T,B and NK) after induction therapy with Dara-CTD. The T cells number recovery after two consolidation cycles post-ASCT,but B and NK cells remain low after the same period. There was a slowly but continuously recovering of B and NK cells,suggesting that Dara-CTD combination allows lymphocytes reconstitution. Analyzing the B cells subpopulations, thenaive B cell was the first to show a more significant recovery, although it was below the reference range (33 – 259). Inconclusion, this is the first study that report the lymphocyte profile during Dara-CTD treatment. This preliminary datasuggest that Dara-CTD induces general lymphopenia on (T, B and NK) populations after induction phase. It wasidentified that T cells recovery was complete after two consolidations cycles while the recovery of B and NK cells wasslowly but continuously.
first_indexed 2024-12-16T08:33:01Z
format Article
id doaj.art-4e5c088bc9124f66a4322a1954e36800
institution Directory Open Access Journal
issn 2531-1379
language English
last_indexed 2024-12-16T08:33:01Z
publishDate 2021-10-01
publisher Elsevier
record_format Article
series Hematology, Transfusion and Cell Therapy
spelling doaj.art-4e5c088bc9124f66a4322a1954e368002022-12-21T22:37:49ZengElsevierHematology, Transfusion and Cell Therapy2531-13792021-10-0143S440EFFECTS OF DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE (C), THALIDOMIDE (T) AND DEXAMETHASONE (D) COMBINATION ON LYMPHOCYTE POPULATIONS OF TRANSPLANT ELIGIBLE NEWLY DIAGNOSE MULTIPLE MYELOMA PATIENTSA Santos0H Santos1J Santos2L Lucas3M Salvino4A Almeida5M Santos6A Torres7MG Arruda8EQ Crusoe9Immunology and Cytometry Lab, Universidade Federal da Bahia (UFBA), Salvador, BA, BrazilImmunology and Cytometry Lab, Universidade Federal da Bahia (UFBA), Salvador, BA, Brazil; Hematology, Hospital Universitário Professor Edgard Santos (HUPES), Universidade Federal da Bahia (UFBA), Salvador, BA, BrazilHematology, Instituto D'or de Pesquisa e Ensino (IDOR) e Clinica CEHON, Salvador, BA, BrazilHematology, Instituto D'or de Pesquisa e Ensino (IDOR) e Clinica CEHON, Salvador, BA, BrazilHematology and Bone Marrow Transplantation, Hospital Universitário Professor Edgard Santos (HUPES), Universidade Federal da Bahia (UFBA), Salvador, BA, BrazilHematology and Bone Marrow Transplantation, Hospital Universitário Professor Edgard Santos (HUPES), Universidade Federal da Bahia (UFBA), Salvador, BA, BrazilImmunology and Cytometry Lab, Universidade Federal da Bahia (UFBA), Salvador, BA, BrazilImmunology and Cytometry Lab, Universidade Federal da Bahia (UFBA), Salvador, BA, BrazilHematology, Instituto D'or de Pesquisa e Ensino (IDOR) e Clinica CEHON, Salvador, BA, BrazilHematology, Hospital Universitário Professor Edgard Santos (HUPES), Universidade Federal da Bahia (UFBA), Salvador, BA, BrazilBackground: The CTD combination have both an immunomodulatory and immunosuppressive activity on multiplemyeloma (MM) patients (pts) treatment. The advance of immunotherapy has been demonstrated by the development ofnew agents like anti CD38-antibody Dara, that are increasing the overall and progression-free survival of MM pts. Daraeffect on the immune system was already described, but few studies analyzed specifically lymphocytes population. Wehypothesized that Dara-CTD combination could impact on lymphocytes subsets during treatment.Aims: The primary endpoint was to quantify subpopulations of lymphocytes in pts with newly diagnosed multiplemyeloma (NDMM) transplant eligible (TE) pts, during Dara-CTD treatment phases (induction, consolidation andmaintenance). Secondary endpoint was to describe B cells subsets during the same phases Methods: Peripheral blood of 14 pts at four different time points was collected: at diagnose, after four cycles of Dara-CTD, after two consolidation cycles post-autologous stem cell transplantation (ASCT) and before maintenance therapy.Flow cytometry was used to detect lymphocyte surface molecules including CD3, CD4, CD5, CD8, CD16, CD19, CD20,CD38, CD45 and CD56 in the scatter plot. B cells were isolated and subpopulations (naïve B cells, non-class switchedmemory B cells, class switched memory B cells, IgD-CD27- memory B cells and plasmablasts) were detected by CD20,CD24, CD27, CD38, CD45 and IgD. Statistics was performed using the SPSS®v25.0 Results: The pts median age was 55 range (41-65) years old, and 57% were female. The median of T, B and NKlymphocytes subsets at diagnosis were 1153 x 10³/μL, 205x 10³/μL and 284 x 10³/μL cells, respectively. After four cyclesof Dara-CTD the median of T, B and NK cells dropped significantly to 889 x 10³/μL, 12 x 10³/μL and 11 x 10³/μL,respectively (p<0.05). The number of the cells after two consolidation cycles post-ASCT, showed T cells full recovery(1087 x 10³/μL) while B and NK cells had weakly reconstitution (15 x 10³/μL and 34 x 10³/μL, respectively). Beforemaintenance therapy, the median of T, B and NK cells were 1456 x 10³/μL, 24 x 10³/μL and 33 x 10³/μL, respectively.Regarding B cell population, the median of naïve B cell decreased after 4 induction cycles from 32 x 10³/μL to 1 x 10³/μL.Then, after two consolidation cycles post-ASCT the number of B cell increased to 14 x 10³/μL and to 18 x 10³/μL beforemaintenance Summary/Conclusion: Lymphopenia have been shown with different protocols using Dara as single agent or incombination. The present study confirmed that there is a decrease in the number of different lymphocytes populations (T,B and NK) after induction therapy with Dara-CTD. The T cells number recovery after two consolidation cycles post-ASCT,but B and NK cells remain low after the same period. There was a slowly but continuously recovering of B and NK cells,suggesting that Dara-CTD combination allows lymphocytes reconstitution. Analyzing the B cells subpopulations, thenaive B cell was the first to show a more significant recovery, although it was below the reference range (33 – 259). Inconclusion, this is the first study that report the lymphocyte profile during Dara-CTD treatment. This preliminary datasuggest that Dara-CTD induces general lymphopenia on (T, B and NK) populations after induction phase. It wasidentified that T cells recovery was complete after two consolidations cycles while the recovery of B and NK cells wasslowly but continuously.http://www.sciencedirect.com/science/article/pii/S2531137921009032
spellingShingle A Santos
H Santos
J Santos
L Lucas
M Salvino
A Almeida
M Santos
A Torres
MG Arruda
EQ Crusoe
EFFECTS OF DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE (C), THALIDOMIDE (T) AND DEXAMETHASONE (D) COMBINATION ON LYMPHOCYTE POPULATIONS OF TRANSPLANT ELIGIBLE NEWLY DIAGNOSE MULTIPLE MYELOMA PATIENTS
Hematology, Transfusion and Cell Therapy
title EFFECTS OF DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE (C), THALIDOMIDE (T) AND DEXAMETHASONE (D) COMBINATION ON LYMPHOCYTE POPULATIONS OF TRANSPLANT ELIGIBLE NEWLY DIAGNOSE MULTIPLE MYELOMA PATIENTS
title_full EFFECTS OF DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE (C), THALIDOMIDE (T) AND DEXAMETHASONE (D) COMBINATION ON LYMPHOCYTE POPULATIONS OF TRANSPLANT ELIGIBLE NEWLY DIAGNOSE MULTIPLE MYELOMA PATIENTS
title_fullStr EFFECTS OF DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE (C), THALIDOMIDE (T) AND DEXAMETHASONE (D) COMBINATION ON LYMPHOCYTE POPULATIONS OF TRANSPLANT ELIGIBLE NEWLY DIAGNOSE MULTIPLE MYELOMA PATIENTS
title_full_unstemmed EFFECTS OF DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE (C), THALIDOMIDE (T) AND DEXAMETHASONE (D) COMBINATION ON LYMPHOCYTE POPULATIONS OF TRANSPLANT ELIGIBLE NEWLY DIAGNOSE MULTIPLE MYELOMA PATIENTS
title_short EFFECTS OF DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE (C), THALIDOMIDE (T) AND DEXAMETHASONE (D) COMBINATION ON LYMPHOCYTE POPULATIONS OF TRANSPLANT ELIGIBLE NEWLY DIAGNOSE MULTIPLE MYELOMA PATIENTS
title_sort effects of daratumumab dara cyclophosphamide c thalidomide t and dexamethasone d combination on lymphocyte populations of transplant eligible newly diagnose multiple myeloma patients
url http://www.sciencedirect.com/science/article/pii/S2531137921009032
work_keys_str_mv AT asantos effectsofdaratumumabdaracyclophosphamidecthalidomidetanddexamethasonedcombinationonlymphocytepopulationsoftransplanteligiblenewlydiagnosemultiplemyelomapatients
AT hsantos effectsofdaratumumabdaracyclophosphamidecthalidomidetanddexamethasonedcombinationonlymphocytepopulationsoftransplanteligiblenewlydiagnosemultiplemyelomapatients
AT jsantos effectsofdaratumumabdaracyclophosphamidecthalidomidetanddexamethasonedcombinationonlymphocytepopulationsoftransplanteligiblenewlydiagnosemultiplemyelomapatients
AT llucas effectsofdaratumumabdaracyclophosphamidecthalidomidetanddexamethasonedcombinationonlymphocytepopulationsoftransplanteligiblenewlydiagnosemultiplemyelomapatients
AT msalvino effectsofdaratumumabdaracyclophosphamidecthalidomidetanddexamethasonedcombinationonlymphocytepopulationsoftransplanteligiblenewlydiagnosemultiplemyelomapatients
AT aalmeida effectsofdaratumumabdaracyclophosphamidecthalidomidetanddexamethasonedcombinationonlymphocytepopulationsoftransplanteligiblenewlydiagnosemultiplemyelomapatients
AT msantos effectsofdaratumumabdaracyclophosphamidecthalidomidetanddexamethasonedcombinationonlymphocytepopulationsoftransplanteligiblenewlydiagnosemultiplemyelomapatients
AT atorres effectsofdaratumumabdaracyclophosphamidecthalidomidetanddexamethasonedcombinationonlymphocytepopulationsoftransplanteligiblenewlydiagnosemultiplemyelomapatients
AT mgarruda effectsofdaratumumabdaracyclophosphamidecthalidomidetanddexamethasonedcombinationonlymphocytepopulationsoftransplanteligiblenewlydiagnosemultiplemyelomapatients
AT eqcrusoe effectsofdaratumumabdaracyclophosphamidecthalidomidetanddexamethasonedcombinationonlymphocytepopulationsoftransplanteligiblenewlydiagnosemultiplemyelomapatients